Earnings results expected in 70 days
Summary
BIO closed Friday lower at €40.6, a decrease of 0.49% from Thursday's close, completing a monthly increase of 1% or €0.4. Over the past 12 months, BIO stock gained 1%.
BIO is not paying dividends to its shareholders.
The last earnings report, released on Nov 07, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Mar 26, 2025.
Biotest AG has completed 1 stock splits, with the recent split occurring on Jul 15, 2015.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XDUS (EUR).
Want to track BIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
BIO Chart
FAQ
What Is the Biotest AG(BIO) Stock Price Today?
The BIO stock price today is €40.60.
What Stock Exchange Does Biotest AG Trade On?
Biotest AG is listed and trades on the XETRA.
What Is the Stock Symbol for Biotest AG?
The stock symbol for Biotest AG is "BIO".
Does Biotest AG Pay Dividends? What's The Current Dividend Yield?
BIO is not paying dividends to its shareholders.
What Is the Biotest AG Market Cap?
As of today, Biotest AG does not have a market cap available.
What is Biotest AG Earnings Per Share?
The Biotest AG EPS is 0.
What Is the Next Biotest AG Earnings Date?
Biotest AG will release its next earnings report on Mar 26, 2025.
Did Biotest AG had any splits?
Biotest AG had 1 splits and the recent split was on Jul 15, 2015.
Biotest AG Profile
| Biotechnology Industry | Healthcare Sector | Mr. Peter Janssen CEO | XDUS Exchange | DE0005227201 ISIN |
| Germany Country | 2,464 Employees | - Last Dividend | 15 Jul 2015 Last Split | - IPO Date |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.
Contact Information
Address: Landsteinerstrasse 5
Phone: 49 61 03 801 0
Website: https://www.biotest.com
2025 © Marketlog. All Rights Reserved.
